series-a
Stage
1
Investors
About
Sartar Therapeutics develops targeted cancer therapies focusing on PDE3A gene-expressing cancers, including gastrointestinal stromal tumor (GIST), through their drug candidate SAR003, a precision treatment inducing cancer cell death.
Explore Sartar Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.